MITRACLIP TRANSCATHETER EDGE-TO-EDGE REPAIR CLINICAL DATA
Standard-Setting clinical outcomes that never stand still, MitraClip is the only TEER therapy with positive durable outcomes to 5 Years.1-5 With unparalleled clinical outcomes, MitraClip has the highest reported MR reduction6, significant improvements in functional status and quality of life6, and is the only TMV therapy that improved survival and HF hospitalization in Secondary MR.7
A SAFE TREATMENT FOR
Treating mitral regurgitation (MR) with MitraClip™ therapy can mean an improved quality of life and relief from the symptoms of heart failure. Clinical studies show intervention with MitraClip transcatheter mitral valve repair (TMVr)—also referred to as TEER (transcatheter edge-to-edge repair)—can safely reduce MR in select patients despite their age or high rate of accompanying serious comorbidities, such as heart failure.8
Evaluating contemporary real-world clinical outcomes in patients treated with MitraClip G4 system.6
Within 12 months in heart failure patients with secondary MR10
EXPAND TREATMENT OPTIONS
FOR SELECT HEART FAILURE PATIENTS
Results from the landmark COAPT™ trial established MitraClip therapy’s impact on heart failure patients with clinically significant secondary MR who remained symptomatic despite maximally tolerated guideline-directed medial therapy. By decreasing MR, patients experienced:
- Improved survival7
- Reduction in HF hospitalizations7
- Improved quality of life9
Relative mortality risk reduction
# Needed to treat to prevent one death*
* Includes crossover patients (GDMT only patients that were allowed to crossover to MitraClip after 24 months).
REAL-WORLD EXPAND STUDIES SHOW UNPARALLED CLINICAL OUTCOMES6,11
The EXPAND and EXPAND G4 studies are prospective, multi-center, single arm, international, post-market, real-world, observational studies of patients who received MitraClip NTR/XTR and MitraClip G4, respectively.6,11
ECL Adjudicated MR Severity
MR Reduction to ≤ Mild at 30 days achieved in 91% of subjects and 98% had MR reduction to ≤ Moderate6
NOTE: Data not from head-to-head studies. Data provided for informational purposes only.
SEE MORE CLINICAL EVIDENCE BY VISITING MITRACLIP.COM
MAT-2115179 v4.0 | Item approved for U.S. use only.